Management Team

Dr. Raymond W. Urbanski M.D., Ph.D.
Chief Executive Officer and Director

Dr. Raymond W. Urbanski, M.D., Ph.D. has been the Chief Executive Officer (CEO) of Applied Biosciences since May 1, 2019. He is a well-established industry leading expert with an impressive background in clinical, research, and pharmaceutical industry expertise across oncology, cardiology, endocrinology, and immunology. Over the course of his career spanning over 20 years, Dr. Urbanski has been responsible for developing and overseeing numerous clinical studies, including Phase 3b and Phase 4 studies, for sunitinib (Sutent), exemestane (Aromasin), irinotecan (Camptosar), epirubicin (Ellence), axitinib, IGF1R inhibitor, and tremilimumab.

Dr. Urbanski joined the Applied BioSciences team having most recently served as Chief Medical Officer and then CEO of GT Biopharma, Inc. (OTCQB: GTBP). Prior to GT Biopharma, Dr. Urbanski served as Chief Medical Officer at Mannkind (NASDAQ: MNKD), Mylan, Inc. (NASDAQ: MYL) and at Metabolex, Inc. While at GT Biopharma and MannKind, Dr. Urbanski was responsible for establishing the R&D organization and leading the overall drug development activities. Most notably in his career, Dr. Urbanski spent eight years with Pfizer (NYSE: PFE), where he held several positions, including Vice President and Chief Medical Officer of the Established Products Business Unit, Senior Medical Director of Oncology Clinical R&D, Senior Medical Director of Breast Cancer Products and Medical Director of Diversified Products. While serving at Pfizer, his leadership accomplishments included the successful development and approval of numerous new drugs and new indications across several therapeutic areas. Prior to serving at Pfizer, Dr. Urbanski served as Vice President and Chief Medical Officer at Suntory Pharmaceuticals, Inc.

Dr. Urbanski received his PhD in Pharmacology from the University of Medicine and Dentistry of New Jersey, Graduate School of Biomedical Sciences (GSBS) and his MD from the New Jersey Medical School.  He was awarded the GSBS Fellowship Award and the Michael W Pozen scholarship during his graduate studies and medical education, respectively. Dr. Urbanski completed his residency and research training at Thomas Jefferson University Hospital in Philadelphia as part of the American Board of Internal Medicine’s Clinical Investigator Pathway. Following his training he joined a large internal medicine practice in Philadelphia while co-founding and serving as President of Clinical Studies Associates (CSA, Inc.), an organization involved in the conduct of clinical studies. During his time in practice and early on in his career in the pharmaceutical industry he held roles of Sub-Investigator, Principle Investigator, and Medical Director in a large number of clinical trials across multiple therapeutic areas. Many led to peer-reviewed publications as well as presentations at national and international conferences.

Martin Schroeder
President – Biopharmaceuticals

Mr. Schroeder was appointed President of our wholly owned subsidiary, Applied Biopharma LLC, in May 2019. Mr. Schroeder has been an advisor to Applied BioSciences, the parent company, since February 2019. Since August 1998, Mr. Schroeder has been Executive Vice President and Managing Director of the Emmes Group, Inc., a strategic advisory firm. Prior to joining the Emmes Group, Mr. Schroeder held a number of industry management and executive positions, including Chairman, President and Chief Executive Officer of AMS, Inc., a venture capital-backed molecular genomics company. From August 2007 through April 2008, Mr. Schroeder was a member of the Board of Directors of Global Clean Energy Holdings, Inc., a public company engaged in the development of nonfood-based bio-fuel feedstock. Mr. Schroeder also played key roles in the founding of Intercept Pharmaceuticals, a public biotech company focused on the treatment of patients with progressive non-viral liver diseases, and the founding of Iovance Biotherapeutics, a public company developing cell therapy products. Mr. Schroeder was also a Visiting Scientist at the U.S. Department of Agriculture following completion of his graduate studies in biochemistry.

Mr. Schroeder holds a Bachelor of Science degree in Biochemistry from the University of California Los Angeles, and a Master of Science degree in Biochemistry from California State University, Long Beach.

Jason Zitzer
Chief Operating Officer – Trace Analytics, Inc.

Jason is an entrepreneur with 18 years of experience in the molecular biology and medical device industries. Recently, he co-founded Applied Genetics and has worked to build the company’s infrastructure to support a national sales force. His responsibilities included integration of a field sales model with three existing laboratory partners in the commercial molecular diagnostics marketplace, managing all financial aspects of the company, and contracting with agencies to drive sales.

Prior to his career at Applied Genetics, Jason contributed to scientific works that lead to publications which focused on the molecular pathogenicity of Helicobacter pylori. After leaving the academic laboratory sector he worked in the commercial genomics field before becoming a distributor for multiple healthcare lines. 

Jason is the co-founder of Trace Analytics, Inc. and serves as COO. His responsibilities include working with industry leaders to establish a cutting-edge process for quality control analysis of agricultural products and managing the company’s bottom line. Currently Jason serves as President of the Laboratory Guild of Washington board and also has been newly elected to the Washington Cannabusiness Association (WACA) Board.

John James “JJ” Southard
President – CBD Products

Mr. Southard is a cannabis advocate and industry-leading expert with an active role in the education and cultivation of the Industry in its early development, with extensive experience in the development of cannabis products focused on the areas of branded, retail and medicinal areas of the industry. Since 2011, Mr. Southard has served as the Chief Executive Officer of Sand Gallery, Inc., a glass-blowing studio and art gallery, located in Steamboat Springs, Colorado, and founded by Mr. Southard. From 2008 until 2011, Mr. Southard founded and served as Chief Executive Officer of Natural Choice Co-Op, LLC, a cannabis dispensary located in Steamboat Springs, Colorado. In 2000, Mr. Southard obtained a Bachelor of Arts (Psychology) from University of Wyoming.